Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK216 and Vincristine in Relapsed or Refractory Ewing's Sarcoma
NCT05046314Phase 2Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Mar 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TK216 in Ewing sarcoma, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Mar 2024; status: completed.
02
Drugs
TK216
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT05046314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05046314.